Correction: Licochalcone A mitigates cisplatin-induced nephrotoxicity by inhibiting ferroptosis and mitochondrial dysfunction via the Nrf2/GPX4 axis
Frontiers in Pharmacology · 12.06.2026 · 17
DOI: 10.3389/fphar.2026.1876105 ↗Kurz gefasst
Korrektur in der Zeitschrift Frontiers in Pharmacology, online erschienen am 12.06.2026. Verfasst von Mo Han und 8 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Drug Metabolism and Pharmacokinetics, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Key Laboratory of Drug Metabolism and Pharmacokinetics, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China.
- Department of Pharmacy and Institute of Clinical Pharmacology, General Hospital of Ningxia Medical University, Yinchuan, China.
Zitieren
APA
Han, M., Zhang, F., Li, M., Zhang, Q., Shen, K., Zhang, D., Xu, H., Zhou, F., & Wang, X. (2026). Correction: Licochalcone A mitigates cisplatin-induced nephrotoxicity by inhibiting ferroptosis and mitochondrial dysfunction via the Nrf2/GPX4 axis. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1876105
Vancouver
Han M, Zhang F, Li M, Zhang Q, Shen K, Zhang D, et al. Correction: Licochalcone A mitigates cisplatin-induced nephrotoxicity by inhibiting ferroptosis and mitochondrial dysfunction via the Nrf2/GPX4 axis. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1876105
BibTeX
@article{Han2026,
author = {Han, Mo and Zhang, Feihu and Li, Mengyuan and Zhang, Qixiang and Shen, Kaidi and Zhang, Depeng and Xu, Huanke and Zhou, Fang and Wang, Xinyu},
title = {Correction: Licochalcone A mitigates cisplatin-induced nephrotoxicity by inhibiting ferroptosis and mitochondrial dysfunction via the Nrf2/GPX4 axis},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1876105}
}
EUVIMED